146 results
Search Results
102. Disposition of quercetin in man after single oral and intravenous doses
103. Pharmacodynamics, pharmacokinetics and metabolism of digitoxin and derivatives in cats
104. The effect of ranitidine and cimetidine on imipramine disposition
105. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man
106. Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function
107. High haemodialysis clearance of ornidazole in the presence of a negligible renal clearance
108. Pharmakokinetik von Triamteren bei Probanden und Patienten mit Leber- und Nierenfunktionsstörungen
109. Pharmacokinetics of theophylline and its metabolites in rabbits
110. Pharmacokinetics of carteolol in relation to renal function
111. Almitrine bismesylate disposition in the human digestive tract
112. Felodipine reduces the absorption of theophylline in man
113. The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates: I. Lignocaine
114. Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols
115. Species differences in butadiene metabolism between mice and rats evaluated by inhalation pharmacokinetics
116. Pharmacokinetics of diltiazem in severe renal failure
117. Antipyrine metabolite formation and excretion in patients with chronic renal failure
118. Pharmacokinetics and metabolism of tomoxiprole, a new analgesic antiinflammatory agent, in the rat
119. Lack of clinically important interaction between erythromycin and theophylline
120. Pharmacokinetics of a single oral dose of hydroflumethiazide in health and in cardiac failure
121. Inhalation pharmacokinetics of 1,2-epoxybutene-3 reveal species differences between rats and mice sensitive to butadiene-induced carcinogenesis
122. Metabolic fate of 125I-tetanus toxin in the spinal cord of rats and cats with early local tetanus
123. Metabolism of pindolol in patients with renal failure
124. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment
125. Disposition and metabolism of 3-hydrazino-6-[N,N-bis(2-hydroxyethyl)amino] pyridazine dihydrochloride in man
126. Pharmacokinetics of chlordesmethyldiazepam after single-dose oral administration in humans
127. Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic
128. Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects
129. Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man
130. Pharmacokinetics of halogenated ethylenes in rats
131. Pharmacokinetics of triamcinolone acetonide and its phosphate ester
132. Mechanism of warfarin potentiation by amiodarone: Dose — and concentration — Dependent inhibition of warfarin elimination
133. Pharmacokinetics of pentachlorophenol in man
134. The physiological disposition of etilefrine in man
135. Effect of miocamycin on theophylline kinetics in children
136. Inhalation pharmacokinetics based on gas uptake studies: I. Improvement of kinetic models
137. Pharmacokinetics of tenoxicam in patients with impaired renal function
138. The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates: III. Mepivacaine
139. Elimination von Desacetylcefotaxim bei geriatrischen Patienten mit Multimorbidität
140. Metabolic disposition of rolziracetam* in laboratory animals
141. Human metabolism of tolfenamic acid. I. Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites
142. HPLC in pharmacokinetics and metabolism studies
143. Pharmacokinetics of penbutolol and its metabolites in renal insufficiency
144. Über Verteilungsraum und Halbwertszeit von intravenös injiziertem Heparin
145. Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses
146. Ursachen der Potenzierung der hypoglykämischen Wirkung von Sulfonylharnstoff-Derivaten durch Medikamente: II. Pharmakokinetik und Metabolismus von Glibenclamid (HB 419) in Gegenwart von Phenylbutazon
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.